porcin
reproduct
respiratori
syndrom
prr
econom
devast
diseas
pig
caus
estim
direct
loss
greater
million
annual
us
pork
industri
prr
caus
prr
viru
prrsv
envelop
positivesens
rna
viru
belong
famili
arterivirida
broadli
two
distinct
prrsv
genotyp
european
type
north
american
type
ii
dovepress
dovepress
binjawadagi
et
al
possess
wide
rang
intraand
intergenotyp
genet
antigen
divers
therefor
develop
prevent
measur
control
prr
outbreak
challeng
global
swine
industri
though
modifi
live
viru
mlv
inactiv
prrsv
vaccin
use
sinc
control
diseas
outbreak
remain
unsuccess
live
viru
vaccin
success
reduc
clinic
diseas
invari
implic
spread
mutat
virus
suscept
pig
contrast
avail
inactiv
prrsv
vaccin
safe
fail
elicit
protect
immun
even
homolog
infect
addit
kill
vaccin
antigen
undergo
intracellular
antigen
present
pathway
induc
strong
cytotox
tcell
ctl
respons
necessari
clearanc
intracellular
pathogen
like
virus
thu
research
aim
develop
better
crossprotect
inactiv
prrsv
vaccin
warrant
therefor
sever
innov
strategi
adopt
strengthen
potenc
efficaci
inactivatedkil
prrsv
vaccin
antigen
kag
respect
suitabl
method
viral
inactiv
purif
use
potent
adjuv
rout
effici
deliveri
vaccin
protect
ag
rapid
enzymat
degrad
bodi
sinc
prrsv
infect
primarili
pig
respiratori
tract
target
cell
lung
alveolar
interstiti
macrophag
induct
strong
local
mucos
immun
respiratori
tract
import
intranas
rout
deliveri
vaccin
control
primari
respiratori
infect
shown
great
promis
induct
protect
mucos
ie
local
well
system
immun
poli
lactidecoglycolid
plga
synthet
biodegrad
polym
use
success
particul
deliveri
inactiv
vaccin
adjuv
mycobacterium
tuberculosi
whole
cell
lysat
tb
wcl
shown
augment
immunogen
live
prrsv
vaccin
plgananoparticl
entrap
kill
prrsv
antigen
npkag
without
caus
side
effect
pig
vaccin
rodent
guinea
pig
rabbit
unlik
complet
freund
adjuv
cfa
tb
wcl
free
waterinsolubl
toxic
cell
wall
compon
bacterium
endotoxin
free
contain
watersolubl
compon
therefor
unlik
cfa
tb
wcl
caus
toxic
granulomat
lesion
site
inocul
previous
shown
singl
dose
prrsv
kagentrap
plga
nanoparticl
npkag
elicit
mucos
system
immun
respons
recent
npkag
coadminist
intranas
twice
tb
wcl
induc
crossprotect
antiprrsv
immun
respons
blood
challeng
heterolog
prrsv
associ
signific
reduct
viremia
report
made
use
variou
type
lung
sampl
recent
studi
evalu
viral
load
local
mucos
immun
airway
surfac
lung
parenchyma
also
microscop
lung
histopatholog
vaccin
heterolog
prrsvchalleng
pig
kill
prrsv
vaccin
antigen
kag
prepar
describ
earlier
briefli
north
american
prototyp
prrsv
strain
grown
marc
cell
freezethaw
three
time
harvest
cell
cultur
supernat
subject
clarif
follow
ultracentrifug
pellet
viru
resuspend
pellet
steril
phosphatebuff
salin
pb
subject
ultraviolet
inactiv
nm
hour
prepar
kag
use
vaccin
prepar
restimul
experi
similarli
prepar
kag
challeng
viru
prrsv
strain
use
prepar
whole
cell
lysat
tb
tb
grown
agar
medium
wcl
prepar
describ
previous
briefli
strain
tb
grown
oleic
acidalbuminedextrosecatalas
enrich
difco
agar
plate
becton
dickinson
compani
franklin
lake
nj
usa
bacteri
cell
harvest
centrifug
coloni
scrape
wash
pb
ph
live
bacteri
cell
suspend
g
wet
weight
ml
pb
contain
mm
ethylenediaminetetraacet
acid
edta
becton
dickinson
compani
proteinas
inhibitor
emd
millipor
billerica
usa
dnase
rnase
sigmaaldrich
st
loui
mo
usa
bacteri
cell
wall
disrupt
bead
beater
cell
breakag
obtain
confirm
acid
fast
stain
cell
lysat
centrifug
pellet
unbroken
cell
insolubl
broken
cell
wall
compon
clear
supernatantcontain
water
solubl
fraction
bacterium
harvest
steril
low
protein
bind
membran
filter
endotoxin
level
everi
batch
tb
wcl
confirm
less
accept
level
convent
larg
whiteduroc
crossbr
week
old
wean
pig
procur
swine
herd
seroneg
prrsv
porcin
respiratori
coro
naviru
transmiss
gastroenter
viru
porcin
circo
viru
antibodi
total
pig
randomli
divid
one
ten
group
pigsgroup
vaccin
indic
vaccin
formul
intranas
mlpig
twice
interv
tabl
vaccin
pig
intranas
challeng
postvaccin
day
virul
heterolog
north
american
prrsv
type
ii
strain
median
tissu
cultur
infect
dose
tcid
pig
adjuv
vaccin
entrap
separ
combin
administ
pig
dose
adjuv
mgdosepig
kag
either
low
dose
high
dose
semipurifi
viral
protein
contain
tcid
kill
prrsv
respect
either
entrap
np
unentrap
vaccin
adjuv
dose
test
efficaci
pig
earlier
pig
monitor
daili
respiratori
symptom
rectal
temperatur
bodi
weight
record
everi
third
day
postchalleng
pc
anim
euthan
day
per
approv
protocol
institut
anim
care
use
committe
ohio
state
univers
indic
sampl
collect
necropsi
lung
examin
gross
lesion
lobe
lung
sampl
collect
right
cranial
lobe
fix
neutral
buffer
formalin
section
made
stain
hematoxylin
eosin
describ
previous
slide
examin
unbias
certifi
veterinari
pathologist
score
prrsvinduc
inflamm
collect
bronchoalveolar
lavag
fluid
prepar
lung
homogen
isol
lung
mononuclear
cell
necropsi
lung
harvest
bronchoalveolar
lavag
bal
fluid
collect
wash
airway
use
ml
cold
pb
contain
antibiot
edta
harvest
fluid
centrifug
minut
clarifi
bal
fluid
aliquot
store
lung
homogen
prepar
describ
previous
briefli
gram
lung
tissu
right
cranial
lobe
everi
pig
collect
ml
icecold
dulbecco
modifi
eagl
medium
minc
homogen
use
stomach
laboratori
blender
seward
limit
worth
west
sussex
uk
minut
clarifi
supernat
lung
homogenatelung
lysat
aliquot
store
lung
mononuclear
cell
lmnc
individu
pig
lung
isol
treat
perfus
minc
lung
tissu
use
collagenas
dnase
describ
previous
estim
total
immunoglobulin
ig
total
isotyp
specif
pig
ig
level
estim
elisa
describ
previous
modif
briefli
enzymelink
immunosorb
assay
elisa
plate
coat
pretitr
dilut
goat
assay
perform
previous
describ
avid
prrsvspecif
antibodi
lung
prrsvspecif
antibodi
avid
determin
describ
previous
modif
briefli
bal
fluid
lung
homogen
sampl
ad
prrsvagcoat
block
plate
hour
incub
test
sampl
room
temperatur
wash
plate
treat
serial
twofold
dilut
ammonium
thiocyan
nh
cn
solut
mol
concentr
incub
room
temperatur
minut
plate
wash
remain
step
elisa
carri
describ
calcul
purpos
od
valu
test
sampl
nh
cnuntreat
well
consid
absorb
contribut
prrsvspecif
antigenantibodi
interact
od
valu
test
sampl
differ
molar
concentr
nh
cn
use
calcul
percent
remain
antigenantibodi
interact
compar
absorb
valu
estim
prrsvspecif
antibodi
subtyp
total
prrsvspecif
subtyp
lung
homogen
sampl
analyz
describ
previous
modif
briefli
kagcoat
plate
block
serial
tenfold
dilut
lung
homogen
ad
mous
antipig
abd
serotec
raleigh
nc
usa
dilut
secondari
antibodi
ad
detect
virusspecif
subtyp
respect
wash
plate
treat
goat
antimous
igghrp
sigmaaldrich
dilut
reaction
develop
use
tmb
substrat
kpl
gaithersburg
md
usa
stop
use
phosphor
acid
plate
read
od
calcul
prrsvspecif
antibodi
level
test
sampl
od
valu
obtain
dilut
consid
determin
prrsvspecif
inter
feron
gamma
secret
cell
enzymelink
immunospot
elispot
assay
elispot
assay
perform
describ
previous
adjuv
plga
nanoparticl
prrsv
vaccin
immun
pig
lung
late
includ
posit
neg
control
respect
lung
homogen
analyz
pig
cytokin
interleukin
proinflammatori
immunosuppress
transform
growth
factor
beta
elisa
describ
previous
flowcytometr
analys
phenotyp
frequenc
lymphoid
myeloid
cell
popul
event
immunostain
lmnc
determin
flow
cytometri
describ
previous
intracellular
stain
monensin
golgiplug
bd
bioscienc
ad
last
hour
incub
lmnc
unstimul
stimul
prrsv
kag
describ
lmnc
first
immunostain
use
pig
lymphocytespecif
monoclon
antibodi
conjug
differ
fluorochrom
cell
fix
paraformaldehyd
permeabil
cellpermeabil
buffer
deioniz
water
pb
ca
mg
formaldehyd
solut
saponin
overnight
cell
wash
stain
fluorochromeconjug
antipig
isotyp
control
monoclon
antibodi
bd
bioscienc
saponin
contain
fluoresc
activ
cell
sort
fac
buffer
immunostain
lmnc
acquir
use
fac
aria
ii
bd
bioscienc
flow
cytomet
analyz
use
flowjo
softwar
treestar
inc
ashland
usa
specif
immun
cell
frequenc
present
percent
total
lymphocyt
myeloid
cell
determin
prrsv
load
virusneutr
antibodi
titer
rna
copi
prrsv
titer
virusneutr
vn
titer
bal
fluid
lung
homogen
sampl
analyz
indirect
immunofluoresc
assay
previous
describ
extract
rna
revers
transcrib
complimentari
deoxyribonucl
acid
cdna
use
quantitect
revers
transcript
kit
qiagen
venlo
netherland
cdna
subject
quantit
realtim
polymeras
chain
reaction
qpcr
use
primer
prrsv
perfecta
sybr
green
fast
mix
quanta
bioscienc
gaithersburg
md
usa
forward
primer
gataaccacgcatttgtcgtc
revers
primer
tgccgttgttatttggcata
standard
curv
gener
use
serial
tenfold
dilut
prrsv
stock
viru
start
tcid
per
viral
rna
quantif
data
express
mean
standard
error
mean
three
pig
statist
analys
perform
oneway
analysi
varianc
follow
tukey
multipl
comparison
test
unpair
ttest
figur
binjawadagi
et
al
cate
sham
entrap
np
particl
spheric
smooth
surfac
dynam
light
scatter
np
indic
mean
diamet
standard
deviat
nm
sham
nm
npkag
nm
npm
tb
wcl
respect
howev
np
possess
uniform
surfac
electrostat
potenti
mv
vitro
studi
reveal
entrap
antigen
pulsereleas
period
sever
week
normal
physiolog
condit
effici
uptaken
porcin
alveolar
macrophag
detail
physic
biolog
character
npkag
vaccin
use
studi
publish
recent
serum
viruschalleng
pig
group
irrespect
vaccin
histori
week
postchalleng
twofold
threefold
increas
total
igg
amount
observ
data
shown
total
igm
iga
amount
lung
homogen
compar
prrsvchalleng
pig
group
figur
c
howev
level
igg
lung
homogen
bal
fluid
figur
e
igm
iga
bal
fluid
figur
f
pig
group
fourto
fivefold
higher
compar
mock
enhanc
prrsvspecif
antibodi
respons
adjuv
npkagvaccin
pig
prrsvspecif
iga
respons
significantli
higher
bal
fluid
lung
homogen
low
high
dose
adjuv
npkagvaccin
pig
compar
vaccin
trial
group
figur
h
contrast
level
virusspecif
igg
compar
bal
fluid
viruschalleng
pig
group
figur
surprisingli
lung
homogen
significantli
higher
level
virusspecif
igg
observ
group
pig
vaccin
either
dose
figur
suggest
adjuv
npkagvaccin
pig
group
virusspecif
iga
major
antibodi
isotyp
airway
surfac
bal
fluid
iga
igg
isotyp
appear
play
import
role
lung
parenchyma
bind
strength
heterogen
antibodi
cognat
ag
defin
avid
adjuv
npkagvaccin
pig
increas
avid
virusspecif
iga
detect
bal
fluid
low
high
dose
lung
homogen
low
dose
sampl
compar
test
group
figur
interestingli
virusspecif
iga
avid
lung
homogen
pig
receiv
highdos
vaccin
compar
among
test
pig
group
figur
compar
level
avid
prrsvspecif
igg
antibodi
respons
observ
lung
homogen
test
group
data
shown
data
suggest
enhanc
avid
prrsvspecif
iga
antibodi
persist
rel
longer
period
airway
surfac
adjuv
npkagvaccin
pig
balanc
antibodi
respons
adjuv
npkagvaccin
pig
helper
type
th
immun
respons
measur
quantifi
antigenspecif
igg
antibodi
subtyp
case
pig
higher
level
indic
respons
respect
result
indic
group
pig
compar
level
subtyp
secret
lung
homogen
figur
c
ratio
greater
less
one
indic
respons
respect
lung
adjuv
npkagvaccin
pig
day
balanc
respons
ratio
close
one
detect
figur
pig
group
although
ratio
close
one
detect
amount
virusspecif
subtyp
low
figur
enhanc
prrsvneutral
antibodi
respons
adjuv
npkagvaccin
pig
except
group
mock
pig
challeng
use
heterolog
prrsv
strain
genet
highli
diverg
compar
vaccin
strain
prrsvspecif
vn
titer
analyz
bal
fluid
lung
homogen
sampl
strain
anoth
variant
type
strain
prrsv
access
genet
distinct
strain
addit
vn
titer
also
analyz
antigen
highli
diverg
heterogenotyp
type
prrsv
strain
figur
j
group
pig
lung
vn
titer
significantli
higher
mean
titer
low
high
vaccin
dose
respect
compar
test
group
figur
f
vn
titer
prrsv
strain
significantli
greater
group
pig
receiv
highdos
vaccin
compar
group
group
respect
figur
j
kag
solubl
wclvaccin
pig
group
also
significantli
higher
vn
titer
prrsv
strain
compar
group
anim
figur
result
indic
solubl
tb
wcladjuv
npkag
vaccin
elicit
broadli
crossreact
vn
titer
vn
titer
observ
bal
fluid
low
data
shown
standard
refer
measur
cmi
respons
prrsv
determin
frequenc
virusspecif
isc
elispot
assay
lowdos
vaccin
group
pig
significantli
increas
isc
lmnc
detect
compar
three
test
group
figur
compar
test
group
highdos
categori
figur
quantiti
detect
lung
homogen
significantli
higher
group
pig
compar
group
low
dose
group
high
dose
categori
figur
h
anoth
import
cytokin
significantli
modul
among
test
pig
group
high
vaccin
dose
categori
figur
lowdos
group
significantli
higher
level
detect
compar
group
figur
one
import
proinflammatori
cytokin
significantli
reduc
lung
vaccin
trial
group
compar
mockchalleng
anim
figur
cytokin
immunosuppress
natur
play
vital
role
prrsv
pathogenesi
quantiti
significantli
reduc
group
pig
compar
group
figur
k
quantiti
among
test
vaccin
trial
pig
group
compar
figur
l
figur
b
frequenc
intracellular
cell
lmnc
either
unstimul
stimul
ag
identifi
virusspecif
memori
lymphocyt
respons
significantli
increas
prrsvspecif
recal
respons
detect
lymphocyt
subset
group
pig
vaccin
high
dose
vaccin
figur
data
suggest
thelper
ctl
potenti
prime
lung
group
pig
prrsvspecif
secret
lymphocyt
subset
restimul
cell
compar
among
differ
vaccin
trial
group
group
anim
vaccin
dose
significantli
increas
cell
compar
group
anim
figur
n
cell
frequenc
significantli
enhanc
group
pig
present
compar
group
low
vaccin
dose
group
high
vaccin
dose
figur
similarli
cell
significantli
higher
group
pig
compar
pig
group
figur
pq
increas
frequenc
activ
cell
detect
group
pig
compar
group
tabl
b
although
signific
differ
total
natur
killer
nk
cell
frequenc
figur
r
increas
nk
cell
frequenc
signific
group
pig
compar
test
group
figur
addit
macrophag
slaii
dendrit
cell
slaii
rich
apc
popul
significantli
higher
group
pig
highdos
vaccin
categori
compar
group
anim
figur
u
lowdos
categori
though
similar
trend
detect
data
statist
signific
figur
bal
fluid
pig
group
low
vaccin
dose
detect
replic
prrsv
rel
reduc
signific
compar
vaccin
group
figur
pig
group
high
vaccin
dose
detect
replic
viru
absent
data
statist
signific
compar
pig
group
figur
lung
homogen
group
pig
receiv
lowdos
vaccin
detect
replic
viru
load
significantli
reduc
compar
mockchalleng
pig
figur
detect
viru
absent
highdos
group
pig
data
statist
signific
compar
pig
group
figur
prrsv
rna
copi
number
bal
fluid
lung
homogen
quantifi
qpcr
lung
sampl
adjuv
plga
nanoparticl
prrsv
vaccin
immun
pig
lung
type
group
pig
lowdos
vaccin
categori
reduct
signific
viral
rna
copi
number
observ
compar
vaccin
trial
group
figur
g
pig
group
vaccin
high
dose
signific
reduct
fold
rna
load
detect
compar
group
anim
figur
h
gross
lung
lesion
reveal
mark
consolid
pig
group
group
pig
lung
compar
mock
anim
group
pig
lung
mock
group
anim
microscop
lmnc
isol
day
necropsi
unstimul
stimul
kill
prrsv
ag
immunostain
use
combin
indic
pig
lymphocytespecif
cell
surfac
marker
follow
intracellular
analyz
flow
cytometri
repres
histogram
show
stimul
total
lymphocyt
lmnc
intracellular
b
dot
line
isotyp
control
solid
line
specif
stain
unstimul
clear
bar
stimul
black
bar
lmnc
kill
prrsv
ag
analyz
total
lymphocyt
ce
stimul
lmnc
compar
indic
lymphocyt
subset
f
n
g
h
p
q
total
nk
j
r
cell
k
also
immunostain
potenti
apc
macrophagerich
slaii
l
dendrit
cellrich
slaii
u
popul
bar
indic
averag
frequenc
indic
cell
three
pig
standard
error
mean
asterisk
indic
statist
signific
differ
two
indic
pig
group
unpair
ttest
appli
compar
data
ce
data
oneway
anova
follow
tukey
ttest
use
figur
ii
iii
v
data
consist
gross
lung
lesion
especi
pig
group
also
pig
group
irregular
fever
reduc
feed
intak
first
week
postchalleng
contrast
absenc
clinic
prr
diseas
gross
lung
lesion
group
pig
associ
absenc
detect
microscop
lung
patholog
lung
architectur
compar
mock
pig
figur
vi
pig
group
moder
reduc
lung
lesion
group
kag
tb
wcl
figur
iv
suggest
adjuv
mediat
protect
immun
respons
pig
similar
sever
lung
patholog
observ
pig
receiv
low
vaccin
dose
group
data
shown
potent
mucos
vaccin
pathogen
predominantli
caus
diseas
mucos
site
proven
efficaci
vaccin
influenza
parainfluenza
adjuv
plga
nanoparticl
prrsv
vaccin
immun
pig
lung
respiratori
syncyti
viru
rotaviru
hivsiv
sinc
prrsv
primarili
infect
lung
pig
effect
control
appear
possibl
induct
strong
respiratori
mucos
immun
thu
develop
novel
prrsv
mucos
vaccin
warrant
among
mucos
rout
intranas
deliveri
npbase
vaccin
elicit
higher
longer
durat
igg
iga
antibodi
respons
compar
rectal
oral
intramuscular
rout
lung
prrsv
infect
alveolar
interstiti
macrophag
greater
bal
cell
macrophag
investig
antiprrsv
respons
bal
cell
lmnc
apc
richli
present
lung
bal
cell
lmnc
differ
antigen
present
potenti
apc
present
lung
mucos
surfac
repres
bal
cell
activ
antigenprim
tcell
apc
lung
parenchyma
repres
lmnc
activ
antigenprim
tcell
therefor
studi
comprehens
investig
overal
immun
respons
viral
load
lung
pig
vaccin
challeng
intranas
rout
coupl
earlier
studi
show
hypergammaglobulinemia
serum
prrsvinfect
pig
indic
fourto
fivefold
increas
total
igg
level
week
postinfect
consist
observ
studi
approxim
fourfold
increas
total
igg
amount
observ
serum
lung
sampl
bal
fluid
lung
homogen
howev
lung
homogen
adjuv
npkagvaccin
pig
total
igg
level
twofold
compar
mock
anim
data
suggest
adjuv
npkag
strong
posit
influenc
humor
respons
indic
signific
increas
product
antiprrsv
antibodi
virusspecif
high
avid
vn
antibodi
titer
inactiv
vaccin
safe
suitabl
adjuv
deliveri
system
critic
boost
efficaci
sever
unsuccess
attempt
made
develop
protect
kill
prrsv
vaccin
recent
studi
use
uvor
beiinactiv
prrsv
tcid
per
dose
coadminist
either
freund
incomplet
suvaxyn
oilwat
adjuv
elicit
vn
titer
greater
associ
partial
clearanc
homolog
viral
challeng
studi
cmi
respons
investig
plga
food
drug
administr
fda
approv
agent
plgabas
intranas
deliveri
prrsv
vaccin
found
safe
pig
one
strategi
augment
uptak
particul
antigen
apc
increas
surfac
hydrophil
natur
particl
coat
nonion
surfact
polaxam
effici
adjuv
critic
promot
strong
cmi
respons
subunit
inactiv
viru
vaccin
watersolubl
compon
tb
wcl
heat
shock
proglupp
potent
adjuv
addit
four
watersolubl
compon
tb
wcl
shortand
longchain
polypeptidoglycan
acetyl
peptidoglycan
tetrasaccharideheptapeptid
potent
adjuv
effect
compar
cfa
induc
product
antibodi
rabbit
coadminist
inactiv
influenza
viru
vaccin
plganp
vaccin
coadminist
potent
adjuv
elicit
protect
immun
respons
demonstr
potent
adjuv
effect
tb
wcl
prrsmlv
also
npkag
side
effect
initi
studi
use
singl
dose
npkag
elicit
partial
crossprotect
immun
respons
pig
potenti
efficaci
npkag
vaccin
recent
studi
npkag
evalu
coadminist
intranas
twice
either
entrap
unentrap
tb
wcl
result
suggest
combin
npkag
unentrap
tb
wcl
significantli
clear
challeng
heterolog
viru
circul
support
strong
humor
cmi
respons
blood
enhanc
tand
bcell
respons
adjuv
npkagvaccin
pig
attribut
concert
effect
plga
tb
wcl
induct
strong
local
mucos
immun
clearanc
heterolog
prrsv
vaccin
pig
lung
import
effect
control
prr
therefor
studi
investig
immun
respons
exclus
mucos
surfac
parenchyma
pig
lung
result
indic
adjuv
npkag
group
pig
potenti
antiprrsv
immun
respons
lung
indic
follow
paramet
increas
prrsvspecif
igg
iga
respons
enhanc
antibodi
avid
vn
titer
balanc
immun
respons
upregul
secret
downregul
immunosuppress
cytokin
enhanc
frequenc
isc
produc
cell
cell
nk
cell
expand
frequenc
apc
importantli
complet
clearanc
detect
replic
challeng
heterolog
prrsv
tenfold
reduct
viral
rna
load
lung
microscop
lung
lesion
figur
strongli
support
observ
viru
clearanc
immunolog
respons
previou
studi
pig
immun
adjuv
npkag
increas
frequenc
cell
restimul
pbmc
detect
stimul
lmnc
increas
popul
cell
observ
perhap
indic
induct
thelper
ctl
memori
respons
lung
like
pbmc
increas
compar
frequenc
lymphocyt
subset
restimul
unstimul
cell
observ
lmnc
group
pig
suggest
teffector
nk
cell
activ
secret
lung
prrsvchalleng
infect
due
lack
similar
data
lymphocyt
vaccin
pig
isol
prior
challeng
difficult
demarc
vaccinealon
induc
respons
npbase
deliveri
vaccin
facilit
affin
matur
activ
b
cell
lead
high
avid
antibodi
product
also
cmi
respons
avid
prrsvspecif
iga
antibodi
isotyp
significantli
higher
bal
fluid
adjuv
npkagvaccin
pig
lung
homogen
lowdos
highdos
adjuv
npkagvaccin
pig
high
avid
iga
respons
observ
reason
discrep
could
time
lung
sampl
collect
overal
result
suggest
virusspecif
function
iga
respons
mucos
tissu
lung
enhanc
adjuv
npkagvaccin
pig
result
indic
lung
mucos
surfac
iga
isotyp
appear
play
import
role
lung
parenchyma
iga
igg
isotyp
contribut
protect
immun
respons
vn
antibodi
put
neutral
epitop
prrsv
glycoprotein
play
import
role
prrsv
clearanc
group
pig
high
level
crossreact
vn
titer
detect
challeng
prrsv
strain
anoth
heterolog
type
ii
viral
strain
importantlyeven
highli
variant
heterogenotyp
strain
prrsv
confirm
broadli
crossprotect
natur
adjuv
npkag
vaccin
formul
prrsv
antibodi
avid
result
posit
correl
vn
titer
agreement
previou
report
typic
kill
vaccin
elicit
predominantli
respons
npbase
vaccin
drive
either
balanc
respons
requir
effici
clearanc
viru
group
pig
enhanc
balanc
humor
cmi
respons
detect
robust
cmi
respons
essenti
complet
protect
prrsv
crucial
cytokin
produc
nk
cell
cell
cell
cell
enhanc
secret
presenc
increas
frequenc
memori
cell
lung
adjuv
npkagvaccin
pig
confirm
addit
effect
plgamedi
deliveri
adjuvant
tb
wcl
possibl
mechan
improv
cmi
respons
group
pig
mediat
crosspresent
plgaentrap
ag
cell
mhc
class
molecul
dendrit
cell
macrophag
thu
result
consist
previou
report
plga
npbase
vaccin
elicit
strong
effector
memori
cmi
respons
addit
increas
level
anoth
import
cytokin
detect
lung
adjuv
npkagvaccin
pig
associ
reduc
product
immunosuppress
cytokin
play
vital
role
prrsv
pathogenesi
cell
present
high
frequenc
pig
involv
innat
adapt
immun
mucos
tissu
enhanc
frequenc
activ
cell
lung
group
pig
observ
significantli
reduc
product
group
pig
indic
absenc
inflammatori
respons
lung
group
pig
import
immedi
avail
unentrap
potent
adjuv
intranas
deliv
npkag
vaccin
critic
studi
inadequ
immun
respons
incomplet
viral
clearanc
observ
vaccin
formul
pig
receiv
plgaentrap
hepat
b
subunit
vaccin
coadminist
encapsul
adjuv
fail
induc
strong
antibodi
respons
consist
result
observ
group
pig
npkag
npwcl
pig
vaccin
adjuv
kag
unentrap
formul
group
exhibit
weak
respons
associ
partial
clearanc
replic
prrsv
presenc
fold
fewer
prrsv
rna
copi
lung
adjuv
npkagvaccin
pig
absenc
detect
replic
challeng
viru
consist
previou
report
wherein
qpcr
fail
differenti
infecti
noninfecti
viru
inactiv
prrsv
rel
stabl
environ
sampl
low
level
prrsv
rna
copi
cell
cultur
method
fail
detect
replic
viru
plgabas
vaccin
deliveri
shown
dramat
reduc
requir
vaccin
dose
time
plganpbas
vaccin
deliveri
get
global
recognit
effect
deliveri
subunitinactiv
mucos
vaccin
size
content
cell
target
properti
engin
studi
demonstr
plgabas
adjuv
npkag
vaccin
induc
strong
antiprrsv
immun
system
local
lung
conclus
intranas
coadministr
plganpentrap
inactiv
prrsv
vaccin
potent
adjuv
potenti
induc
superior
crossprotect
intern
journal
nanomedicin
submit
manuscript
wwwdovepresscom
adjuv
plga
nanoparticl
prrsv
vaccin
immun
pig
lung
immun
pig
futur
studi
aim
fraction
tb
wcl
identifi
adjuv
compon
npkag
identifi
altern
adjuv
reduc
cost
vaccin
formul
perform
field
trial
valid
efficaci
innov
vaccin
deliveri
approach
studi
establish
util
nanotechnologybas
vaccin
larg
anim
also
envisag
potenti
applic
import
human
respiratori
pathogen
